Germany’s Merck KGaA will market Xian Janssen’s Inovokana® in China. Inovokana, a novel treatment for type 2 diabetes, is a member of the relatively new sodium-glucose co-transporter 2 (SGLT-2) class of oral diabetes treatments. In China, Merck already distributes Glucophage® (metformin hydrochloride) and other diabetes products, while Janssen has no presence in the sector. Approved almost one year ago for China use, Inovokana is the market leader globally among SGLT-2 offerings, though it will be third to market in China.
Source: China Biotoday
